Effect of calcium and vitamin D in treatment of gestational diabetes

Effect of calcium and vitamin D co-supplementation on insulin resistance and inflammatory factors in women with gestational diabetes

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201311205623N11

Enrollment

Registered

2013-12-01

Start date

2013-11-20

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes mellitus. Diabetes mellitus in pregnancy, unspecified

Interventions

Intervention 1: Intervention group: Vitamin D3 capsule, 50000 IU, every 3 weeks for 6 weeks orally. Intervention group: Calcium tablet, 500 mg, two times a day for 6 weeks orally. Intervention 2: Cont

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Pregnant women aged 18-40 years; diagnosed with GDM at 24-28 weeks' gestation

Exclusion criteria

Exclusion criteria: Subjects with premature preterm rupture of membrane Placenta abruption Pre-eclampsia Eclampsia Chronic hypertension Hypothyroidism Urinary tract infection Smoking Those with kidney or liver diseases Those taking estrogen therapy Stressful life conditions

Design outcomes

Primary

Measure	Time frame
Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.	—

Secondary

Measure	Time frame
Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: t Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.	—

Measure

Time frame

Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: t Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 20, 2026